Tiziana Up After MS Data From Second Patient

 

• Tiziana Life Sciences 
  TLSA+11.1%+ Free Alerts
   reported clinical results from the second patient with Secondary Progressive Multiple Sclerosis (SPMS) in the ongoing study as part of an expanded access program.
• These results confirm the previously reported data from the first SPMS patient after three months of treatment of the first SPMS patient. 
• The treatment with foralumab, a fully human anti-CD3 monoclonal antibody, was well-tolerated and improved clinical and PET imaging analyses.
• After three months of treatment with intranasal foralumab, the patient showed improvement as measured by PET imaging and neurologic examination. 
• Approximately 10-30% reduction in PET signal was seen across brain regions in the second SPMS patient, comparable to the PET changes seen in the first SPMS patient. 
• Clinically, the Timed 25-Foot Walk test and neurologic exam were also improved. 
• The FDA has now allowed Tiziana to treat an additional eight SPMS patients. 
• Although the original dosing regimen with intranasal therapy with foralumab will remain the same (50 mcg), the revised regimen has a dose escalation of up to 100 mcg (MWF), an option to improve clinical benefit.

https://www.benzinga.com/general/biotech/22/06/27610213/tiziana-life-sciences-shares-jump-after-multiple-sclerosis-data-from-second-patient